Marsico Capital Management LLC purchased a new position in shares of Merck & Company, Inc. (NYSE:MRK) during the first quarter, Holdings Channel reports. The firm purchased 447,422 shares of the company’s stock, valued at approximately $28,429,000. Merck & comprises approximately 1.2% of Marsico Capital Management LLC’s holdings, making the stock its 25th largest position.
A number of other large investors also recently added to or reduced their stakes in MRK. HM Capital Management LLC raised its stake in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after buying an additional 15 shares during the last quarter. City Holding Co. raised its stake in Merck & by 0.4% in the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock worth $494,000 after buying an additional 31 shares during the last quarter. Camelot Portfolios LLC raised its stake in Merck & by 0.4% in the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after buying an additional 33 shares during the last quarter. Adirondack Trust Co. raised its stake in Merck & by 0.4% in the first quarter. Adirondack Trust Co. now owns 11,334 shares of the company’s stock worth $720,000 after buying an additional 41 shares during the last quarter. Finally, Northstar Group Inc. raised its stake in Merck & by 0.5% in the first quarter. Northstar Group Inc. now owns 12,778 shares of the company’s stock worth $811,000 after buying an additional 58 shares during the last quarter. 73.73% of the stock is owned by institutional investors and hedge funds.
Shares of Merck & Company, Inc. (NYSE:MRK) traded down 0.1207% during midday trading on Thursday, reaching $62.4146. The company had a trading volume of 1,596,441 shares. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The stock has a market capitalization of $170.71 billion, a PE ratio of 33.7924 and a beta of 0.80. The company’s 50-day moving average is $63.56 and its 200-day moving average is $63.81.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 25.75% and a net margin of 17.14%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 earnings per share. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is 76.11%.
ILLEGAL ACTIVITY WARNING: “Marsico Capital Management LLC Purchases New Stake in Merck & Company, Inc. (NYSE:MRK)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2799106/marsico-capital-management-llc-purchases-new-stake-in-merck-company-inc-nysemrk.html.
A number of equities research analysts recently commented on the company. BidaskClub lowered Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. BMO Capital Markets reissued an “outperform” rating and issued a $73.00 price target (down from $74.00) on shares of Merck & in a research report on Monday, July 24th. HSBC Holdings plc raised Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a research report on Thursday, May 25th. Finally, Jefferies Group LLC reissued a “sell” rating and issued a $51.00 price target on shares of Merck & in a research report on Wednesday, May 24th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $69.80.
In other news, Director C Robert Kidder sold 5,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $63.54, for a total value of $317,700.00. Following the completion of the transaction, the director now owns 14,317 shares of the company’s stock, valued at $909,702.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.05% of the company’s stock.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.